Poseida Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin, I'm required to point out certain disclosures regarding the relationship between Piper and our next presenting company, Poseida, which are represented at the back of the room and also at the registration desk.
So Poseida's developing next-gen cell and gene therapies based on a suite of proprietary technologies, including Super piggyBac gene insertion and Cas-CLOVER gene-editing technologies. It's been a great year for Poseida, having signed a $6-billion partnership with Genentech for hematologic CAR-Ts, including P-BCMA-ALLO1. And we'll actually talk about some of the data that's forthcoming on this pipeline.
But I think a really important part of the deal was that Poseida retained rights to their solid tumor CAR-T programs and will actually present the first-ever Phase 1 data on P-MUC1C-ALLO1 at ESMO I-O next week. Poseida is also developing liver-targeted gene therapies and entered into a transformative alliance with Takeda.
Joining us
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |